An Evaluation of the Cellular and Humoral Response of a Multi-Epitope Vaccine Candidate Against COVID-19 with Different Alum Adjuvants
Pathogens · 2024
DOI: 10.3390/pathogens13121081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2024. Verfasst von Lineth Juliana Vega Rojas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Vaccines Laboratory, Facultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Campus Aeropuerto, Carretera a Chichimequillas…. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, SARS-CoV-2, Alum Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Mexicana de Cooperación para el Desarrollo (AMEXCID), Agencia Mexicana de Cooperación para el Desarrollo (AMEXCID) [Mexican Agency for Cooperation and Development], Universidad Autónoma de Querétaro.
Abstract (Originalsprache)
SARS-CoV-2 (Betacoronavirus pandemicum) is responsible for the disease identified by the World Health Organization (WHO) as COVID-19. We designed “CHIVAX 2.1”, a multi-epitope vaccine, containing ten immunogenic peptides with conserved B-cell and T-cell epitopes in the receceptor binding domain (RBD) sequences of different SARS-CoV-2 variants of concern (VoCs). We evaluated the immune response of mice immunized with 20 or 60 µg of the chimeric protein with two different alum adjuvants (Alhydrogel® and Adju-Phos®), plus PHAD®, in a two-immunization regimen (0 and 21 days). Serum samples were collected on days 0, 21, 31, and 72 post first immunization, with antibody titers determined by indirect ELISA, while lymphoproliferation assays and cytokine production were evaluated by flow cytometry. The presence of neutralizing antibodies was assessed by surrogate neutralization assays. Higher titers of total IgG, IgG1, and IgG2a antibodies, as well as increased proliferation rates of specific CD4+ and CD8+ T cells, were observed in mice immunized with 60 μg of protein plus Adju-Phos®/PHAD®. This formulation also generated the highest levels of TNF-α and IFN-γ, in addition to the presence of neutralizing antibodies against Delta and Omicron VoC. These findings indicate the potential of this chimeric multi-epitope vaccine with combined adjuvants as a promising platform against viral infections, eliciting a TH1 or TH1:TH2 balanced cell response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology and Vaccines Laboratory, Facultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Campus Aeropuerto, Carretera a Chichimequillas, Ejido Bolaños, Querétaro 76140, Mexico.
- Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT), Av. Insurgentes Sur 1582, Alcaldía Benito Juárez, Crédito Constructor, Ciudad de México 03940, Mexico.
- Instituto de Neurobiología UNAM, Laboratorio Universitario del Bioterio, Universidad Nacional Autónoma de México, Querétaro 76230, Mexico.
- Laboratorio de Inmunología, Centro de Investigación en Alimentación y Desarrollo, A.C, Hermosillo 83304, Mexico.
- Advanced Biomedical Research Center, School of Medicine, Universidad Autónoma de Querétaro, Querétaro 76176, Mexico.
- Facultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Av. de las Ciencias s/n, Juriquilla, Querétaro 76230, Mexico.
ORCID-Profile: Lineth Juliana Vega Rojas, Rocío Alejandra Ruíz-Manzano, Jesús Hernández, Teresa García-Gasca, Juan Mosqueda
Förderung
- Agencia Mexicana de Cooperación para el Desarrollo (AMEXCID)
- Agencia Mexicana de Cooperación para el Desarrollo (AMEXCID) [Mexican Agency for Cooperation and Development]
- Universidad Autónoma de Querétaro
Zitieren
APA
Vega Rojas, L. J., Ruíz-Manzano, R. A., Velasco-Elizondo, M. A., Carbajo-Mata, M. A., Hernández-Silva, D. J., Rocha-Solache, M., Hernández, J., Pérez-Serrano, R. M., Zaldívar-Lelo de Larrea, G., García-Gasca, T., & Mosqueda, J. (2024). An Evaluation of the Cellular and Humoral Response of a Multi-Epitope Vaccine Candidate Against COVID-19 with Different Alum Adjuvants. Pathogens. https://doi.org/10.3390/pathogens13121081
Vancouver
Vega Rojas LJ, Ruíz-Manzano RA, Velasco-Elizondo MA, Carbajo-Mata MA, Hernández-Silva DJ, Rocha-Solache M, et al. An Evaluation of the Cellular and Humoral Response of a Multi-Epitope Vaccine Candidate Against COVID-19 with Different Alum Adjuvants. Pathogens. 2024. doi:10.3390/pathogens13121081
BibTeX
@article{VegaRojas2024,
author = {Vega Rojas, Lineth Juliana and Ruíz-Manzano, Rocío Alejandra and Velasco-Elizondo, Miguel Andrés and Carbajo-Mata, María Antonieta and Hernández-Silva, Diego Josimar and Rocha-Solache, Mariana and Hernández, Jesús and Pérez-Serrano, Rosa Martha and Zaldívar-Lelo de Larrea, Guadalupe and García-Gasca, Teresa and Mosqueda, Juan},
title = {An Evaluation of the Cellular and Humoral Response of a Multi-Epitope Vaccine Candidate Against COVID-19 with Different Alum Adjuvants},
journal = {Pathogens},
year = {2024},
doi = {10.3390/pathogens13121081}
}
EUVIMED